Literature DB >> 2877149

Teicoplanin-resistant coagulase-negative staphylococcus.

A P Wilson, M D O'Hare, D Felmingham, R N Grüneberg.   

Abstract

Mesh：

Substances：

Year:  1986        PMID： 2877149     DOI： 10.1016/s0140-6736(86)90622-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  23 in total

1.  Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci.

Authors:  M Bertin; A Muller; X Bertrand; C Cornette; M Thouverez; D Talon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

2.  In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.

Authors:  F Biavasco; R Lupidi; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections.

Authors:  M Berti; G Candiani; M Borgonovi; P Landini; F Ripamonti; R Scotti; L Cavenaghi; M Denaro; B P Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 4.  Resistance of enterococci to glycopeptides.

Authors:  P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

5.  Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria.

Authors:  S Dutka-Malen; R Leclercq; V Coutant; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

6.  Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin.

Authors:  F Brunet; G Vedel; F Dreyfus; J F Vaxelaire; T Giraud; B Schremmer; J F Monsallier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

7.  Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci.

Authors:  F W Goldstein; A Coutrot; A Sieffer; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 8.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

9.  In vitro conjugative transfer of VanA vancomycin resistance between Enterococci and Listeriae of different species.

Authors:  F Biavasco; E Giovanetti; A Miele; C Vignaroli; B Facinelli; P E Varaldo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

10.  Cloning and heterospecific expression of the resistance determinant vanA encoding high-level resistance to glycopeptides in Enterococcus faecium BM4147.

Authors:  A Brisson-Noël; S Dutka-Malen; C Molinas; R Leclercq; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.